From: Jeffrey Epstein <[email protected]> Sent: Wednesday, February 5, 2014 2:52 PM To: Tazia Smith Subject: Re: Gilead entry point.... 5000 shares ok On Wed, Feb 5, 2014 at 9:43 AM, Tazia Smith < Classification: Pu=lic Jeffrey - <mailto » wrote: Gilead = 1.5 in your (and our suggested) US healthcare percentages Gilead reported earnings yesterday, trading —80.34 vs 82.02 prior close. DB Research reiterates the equity as one of our top picks (like big cap biotech, this and BIIB among them, analyst sees room for further multiple expansion). Earnings detail and investment thesis below. —64% implied upside to DB price target of $132 Used with permission of Bloomberg Finance LP Forwarded =y Tazia Smith/db/dbcom on 02/05/2014 09:38 AM From: EVS EquityFocus/db/dbcom@DBEM=A To: Date: 02/05/2014 05:01 AM Subject: DB: GILD.OQ - Robyn Karnauska= Classification: Public Gilead Sciences (Buy, CP: $82.02, TP: $132.00, GILD.OQ, Robyn Karnauskas)</=> 4Q13 update: light taxes create more leverage for Sovaldi 4Q13 product revenues beat consensus by - $250M led by inventory & Sovaldi Sovaldi 4Q13 sales were $139M vs. $75M consensus. Pure demand was roughly $50M in the quarter. Remainder of sales came from inventory stocking & purchase for clinical trials. On the HIV front, mgmt noted that 1Q14 will be EFTA_R1_01758239 EFTA02581643